Auditing the Auditor: What Oversight of CMS Might do to Part D
This article was originally published in RPM Report
The Centers for Medicare and Medicaid Services is famous for auditing the two big government health programs that it runs. But CMS faces audits also. The inspector general's office within HHS is one of the groups that keeps a close eye on CMS. And, like an internal family feud, criticism from within HHS can often be the most frank and painful. CMS is feeling the pain from a review of pharmacy acquisiton costs under Part D;' there is more coming.
You may also be interested in...
Drug prices have lost their headline appeal. That has got to be a relief to pharma execs who have pipeline problems and patent expirations to deal with and don't need to be worried about bad publicity egging on Congress to price-control schemes. But there are new threats to drug prices brewing - and one of them is industry's old nemesis: government rebates.
US FDA asks oncology drug sponsors for information on the impact of modifications to clinical trials during the pandemic – with close attention to remote monitoring and data collection.